SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): July 6, 2004
MIRAVANT MEDICAL TECHNOLOGIES
(Exact name of Registrant as specified in its charter)
Delaware 0-2554 77-0222872
(State or other jurisdiction of (Commission File Number) I.R.S. Employer
incorporation or organization) Identification Number)
336 Bollay Drive
Santa Barbara, CA 93117
(Address of principal executive offices)
(805) 685-9880
(Registrant's telephone number, including area code)
ITEM 5. Other Events
On July 6, 2004, Miravant Medical Technologies (the "Company") announced a
Collaboration Agreement and a Securities Purchase Agreement Guidant Corporation,
a world leader in the treatment of cardiac and vascular disease. Guidant agreed
to provide up to $7 million capital in support of Miravant's PhotoPoint
cardiovascular programs, including an upfront payment of $3 million and
additional staged investments based on the achievement of certain milestones
through Phase I clinical trials. The development programs include regional
treatments for atherosclerosis and atherosclerotic vulnerable plaque.
Pursuant to the Securities Purchase Agreement, on July 6, 2004 the Company
issued 1,112,966 shares of a newly created Series A Preferred Stock (the "Series
A Preferred"). The shares of Series A Preferred are convertible, initially at a
one-for-one ratio based on the purchase price of $2.70 per share, into shares of
the Company's common stock. The Company also granted Guidant registration rights
with respect to the shares of common stock into which the Series A Preferred
Stock are convertible.
The foregoing descriptions of the above transactions and agreements do not
purport to be complete and are qualified in their entirety by reference to the
actual agreements, which will be filed as exhibits to the Company's next
Quarterly Report on Form 10-Q.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
Exhibit Number Exhibit
Exhibit 99.1 Joint Press Release issued by the Company and
ACS/Guidant dated July 6, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act or 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Miravant Medical Technologies
(Registrant)
Date: July 7, 2004
By: /s/ John M. Philpott
-------------------------
Name: John M. Philpott
Title: Chief Financial Officer
Exhibit Index
Exhibit Number Exhibit
Exhibit 99.1 Joint Press Release issued by the Company and ACS/Guidant
dated July 6, 2004.